JenniferALigibelMD

Oncology • Boston, MA

Breast Cancer

Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Ligibel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ligibel's full profile

Already have an account?

Office
44 Binney St
# Mayer
Boston, MA 02115
Phone+1 617-632-5961

Fax+1 617-632-1930

Summary

Dr. Jennifer Ligibel is an oncology specialist based in Boston, MA, with a focus on breast cancer and hereditary breast/ovarian cancer. She completed her medical education with a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Hematology and Medical Oncology at Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute. She has contributed to research with publications in notable journals such as the Journal of Clinical Oncology and BMC Neurology. Dr. Ligibel has been the principal investigator for several clinical trials related to exercise and physical activity in cancer treatment and prevention. Her recognition in the field includes honors such as Regional Top Doctor from Castle Connolly and Super Doctor from SuperDoctors.com.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
Massachusetts General HospitalResidency, Internal Medicine, 1996 - 1999
Washington University in St. Louis School of MedicineClass of 1996

Certifications & Licensure

NH State Medical License 2009 - Present
MA State Medical License 1999 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com

Clinical Trials

Effects of Exercise Intervention on Insulin Levels in Breast Cancer Survivors Start of enrollment: 2003 Dec 01
Completed
Not Applicable
Exercise Intervention in Women With Metastatic Breast Cancer Start of enrollment: 2006 Aug 01
Completed
Not Applicable
The Active After Cancer Trial (AACT) Start of enrollment: 2007 Oct 01
Active, not recruiting
Not Applicable
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
The Preoperative Health & Body Study Start of enrollment: 2011 Aug 01
Active, not recruiting
Not Applicable
RPFNA Assessment of Exercise Effect in Breast Cancer Start of enrollment: 2011 Oct 01
Completed
Not Applicable
Healthy Living After Cancer: Weight Management Pilot Study Start of enrollment: 2013 Nov 01
Completed
Not Applicable
Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors Start of enrollment: 2013 Feb 01
Completed
Phase 3
Breast Cancer WEight Loss Study (BWEL Study) Start of enrollment: 2016 Aug 01
Active, not recruiting
Phase 3
Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue Start of enrollment: 2018 Sep 17
Active, not recruiting
Not Applicable
Feasibility of Fasting & Exercise in Pts With HR+ MBC Start of enrollment: 2021 Jan 15
Active, not recruiting
Not Applicable
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients Start of enrollment: 2023 Mar 20
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D) Start of enrollment: 2024 Mar 28
Recruiting
Not Applicable
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.
Otto Metzger Filho, Karla Ballman, Jordan Campbell, Minetta Liu, Jennifer Ligibel
Journal of Clinical Oncology. 2025-01-02
Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO).
Kathryn H Schmitz, Justin C Brown, Melinda L Irwin, Kim Robien, Jessica M Scott
Journal of the National Cancer Institute. 2025-01-01
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of D...
Dario Trapani, Qingchun Jin, Kathy D Miller, Hope S Rugo, Katherine E Reeder-Hayes
Clinical Breast Cancer. 2024-12-31

Lectures

BWEL and Beyond: Examining the Diet and Exercise Interventions on Reducing Breast Cancer Recurrences
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Diet and Exercise: Role in Primary Cancer Prevention and Cancer Recurrence
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with earl...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Using Weight Loss to Beat Cancer
ENDO 2018: 100th Endocrine Society Annual Meeting - Chicago, Illinios - 03/18/2018
Toward Precision Cancer Care: Biobehavioral Contributions to the Exposome
American Psychosomatic Society, Chicago, Illinois - 10/26/2012
Join now to see all

Press Mentions

VIDEO: Weight Loss Intervention Increased Physical Activity in Patients with Breast CancerOctober 30th, 2024
VIDEO: ‘Provocative Early Findings’ Show Exercise May Impact Breast Cancer OutcomesOctober 30th, 2024
Post-Treatment Lifestyle Choices Influence Long-Term Outcomes in Breast Cancer PatientsSeptember 16th, 2024
Join now to see all